Across TCGA pan-cancer cohorts, CRYAB Mutation is linked to patient survival in 1 of 34 cancer types, making it a survival-associated CRYAB data layer compared with 28 for mass-spec protein and 6 for mass-spec protein.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where higher CRYAB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRYAB expression acts as an unfavorable survival marker.
KIRC are the cancer types where CRYAB Mutation most reproducibly stratifies survival.